CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients.

Highlights: [•] Agonist form of CXCL10 is undetectable in chronic HCVg4 patients. [•] Increased sDPPIV concentration and DPP activity in HCVg4 patients. [•] CXCL10 expression does not correlate with localization of CXCR3+ cells in liver. [•] Chemokine antagonism as a general mechanism of immune modulation in chronic HCV. [•] Highlights role for DPPIV as a drug target for treatment of HCVg4 patients. [ABSTRACT FROM AUTHOR]